Patrick James Lupardus from Lafayette, CA, age 48

Inducible Self-Cleaving Protease Tag And Method Of Purifying Recombinant Proteins Using The Same
view source
US Patent:

20130012687, Jan 10, 2013
Filed:

Sep 21, 2010
Appl. No.:

13/261221
Inventors:

Matthew Bogyo - Palo Alto CA, US
K. Christopher Garcia - Palo Alto CA, US
Aimee Shen - Palo Alto CA, US
Patrick J. Lupardus - Palo Alto CA, US
International Classification:

C12P 21/06
C07K 14/00
US Classification:

530350, 435 681
Abstract:

A method of purifying a protein is disclosed which entails: a) fusing a site-specific affinity-tagged cysteine protease domain to a target protein to form a tagged fusion protein; b) activating the site-specific cysteine protease domain of the tagged fusion protein by subjecting the site-specific affinity-tagged cysteine protease domain to an inducer, which induces autoprocessing at a cleavage site; thereby releasing untagged target protein; and c) isolating the untagged target protein.

Cytokine Compositions And Methods Of Use Thereof
view source
US Patent:

20120269765, Oct 25, 2012
Filed:

Jul 26, 2010
Appl. No.:

13/386652
Inventors:

K. Christopher Garcia - Menlo Park CA, US
Patrick Lupardus - Menlo Park CA, US
Sashank K. Reddy - Boston MA, US
Gregory J. Sieczkiewicz - Hopkinton MA, US
International Classification:

A61K 38/20
C07K 19/00
C12N 15/24
C12N 15/62
C07K 16/24
A61K 39/395
A61P 29/00
A61P 17/06
A61P 19/02
A61P 1/04
A61P 25/00
C12P 21/02
C12N 5/071
C12N 5/10
C07K 14/54
US Classification:

424 852, 530351, 536 235, 536 234, 5303892, 4241581, 435 6952, 435375, 435348, 435369, 435328
Abstract:

Polypeptides, including non-naturally occurring and recombinantly modified polypeptides related to the p19 subunit of IL-23, methods of making such molecules and methods of using such molecules as therapeutic, prophylactic and diagnostic agents are provided.

Il2 Orthologs And Methods Of Use
view source
US Patent:

20230076768, Mar 9, 2023
Filed:

Jan 14, 2021
Appl. No.:

17/758830
Inventors:

- Menlo Park CA, US
Patrick J. Lupardus - Menlo Park CA, US
Richard B. Murphy - Menlo Park CA, US
Martin Oft - Menlo Park CA, US
International Classification:

C07K 14/715
C12N 15/86
A61P 35/00
Abstract:

The present disclosure provides orthogonal receptors. In some embodiments, the orthogonal receptor is an orthogonal CD122. In some embodiments, the orthogonal receptor is an orthogonal human CD122 (hCD122). In some embodiments, the orthogonal receptor is an orthogonal CD122 comprising at least one STAT3 binding motifs.

Cd122 With Altered Icd Stat Signaling
view source
US Patent:

20230027899, Jan 26, 2023
Filed:

Jan 14, 2021
Appl. No.:

17/783505
Inventors:

- Menlo Park CA, US
Patrick J. Lupardus - Menlo Park CA, US
International Classification:

C07K 14/55
C07K 14/715
C07K 14/725
C12N 15/63
Abstract:

The present disclosure relates to modified human CD122, wherein the modified human CD122 comprises one or more STAT3 binding motifs. In some embodiments, the modified human CD122 is a modified orthogonal human CD122, which can be selectively activated by a cognate orthogonal IL2. The modified human CD122 is able to stimulate robust and sustained STAT3 and STAT5 signaling upon binding to a cognate IL2 ligand.

Isoform-Selective Anti-Tgf-Beta Antibodies And Methods Of Use
view source
US Patent:

20210301005, Sep 30, 2021
Filed:

Mar 18, 2021
Appl. No.:

17/205663
Inventors:

- South San Francisco CA, US
Joseph R. ARRON - South San Francisco CA, US
Daryle DEPIANTO - South San Francisco CA, US
Wendy Green HALPERN - South San Francisco CA, US
WeiYu LIN - South San Francisco CA, US
Patrick J. LUPARDUS - South San Francisco CA, US
Thirumalai Rajan RAMALINGAM - South San Francisco CA, US
Dhaya SESHASAYEE - South San Francisco CA, US
Tianhe SUN - South San Francisco CA, US
Tulika TYAGI - South San Francisco CA, US
Jia WU - South San Francisco CA, US
Yan WU - South San Francisco CA, US
Jian Ping YIN - South San Francisco CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C07K 16/22
A61P 11/00
C07K 16/46
Abstract:

The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.

Anti-Tigit Antibodies And Methods Of Use
view source
US Patent:

20210253693, Aug 19, 2021
Filed:

Apr 29, 2021
Appl. No.:

17/244682
Inventors:

- South San Francisco CA, US
Robert J. JOHNSTON - San Francisco CA, US
Yan WU - Foster City CA, US
Wei-Ching LIANG - Foster City CA, US
Patrick LUPARDUS - Redwood City CA, US
Mahesh YADAV - San Bruno CA, US
Dhaya SESHASAYEE - Cupertino CA, US
Meredith HAZEN - Belmont CA, US
International Classification:

C07K 16/28
C07K 16/30
A61K 39/395
A61K 45/06
A61K 38/17
Abstract:

The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Anti-Tigit Antibodies And Methods Of Use
view source
US Patent:

20210032328, Feb 4, 2021
Filed:

Oct 6, 2020
Appl. No.:

17/064464
Inventors:

- South San Francisco CA, US
Robert J. JOHNSTON - San Francisco CA, US
Yan WU - Foster City CA, US
Wei-Ching LIANG - Foster City CA, US
Patrick LUPARDUS - Redwood City CA, US
Mahesh YADAV - San Bruno CA, US
Dhaya SESHASAYEE - Cupertino CA, US
Meredith HAZEN - Belmont CA, US
International Classification:

C07K 16/28
C07K 16/30
A61K 39/395
A61K 45/06
A61K 38/17
Abstract:

The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Identification Of Immunogenic Mutant Peptides Using Genomic, Transcriptomic And Proteomic Information
view source
US Patent:

20200124616, Apr 23, 2020
Filed:

Jan 3, 2020
Appl. No.:

16/733988
Inventors:

- South San Francisco CA, US
Patrick LUPARDUS - San Francisco CA, US
Ira MELLMAN - San Francisco CA, US
Mahesh YADAV - San Francisco CA, US
Suchit JHUNJHUNWALA - Sunnyvale CA, US
Jennie LILL - Pacifica CA, US
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

G01N 33/68
A61K 39/00
C12Q 1/6886
G01N 33/569
Abstract:

The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.

Patrick James Lupardus